Metropolis Healthcare, India’s second-largest pathology laboratory chain, has garnered a positive outlook from major brokerage firms Nuvama and Emkay following its fiscal fourth-quarter 2026 results. The company reported a significant 74 percent year-on-year increase in consolidated profit after tax to Rs 50.96 crore, driven by robust demand and improved operational efficiencies.
Context of Growth and Market Position
The diagnostic sector in India has experienced a structural shift toward organized players, benefiting firms like Metropolis Healthcare. In the March quarter, the company recorded consolidated revenue from operations of Rs 424.68 crore, up from Rs 345.29 crore in the same period last year. This growth trajectory reflects the company’s ability to capitalize on a stable pricing environment and increased consumer focus on health diagnostics.
Detailed Performance Analysis
Nuvama has maintained a ‘Buy’ rating on the stock with a target price of Rs 541, noting that the firm’s organic revenue and EBITDA grew by 15 percent and 69 percent respectively. This performance was supported by a 9 percent growth in volumes and a 4 percent increase in realization. The management has projected a 14–15 percent compound annual growth rate (CAGR) over the next three years, fueled by aggressive network expansion and digital integration.
Emkay is even more optimistic, assigning a target price of Rs 625, which implies an upside potential of approximately 15.5 percent. Emkay analysts emphasize that Metropolis is well-positioned to leverage industry tailwinds, including productivity gains and network efficiency. The company plans to open 100 new mini-hubs, a strategic move intended to capture a larger share of the diagnostic market.
Operational Efficiency and Financial Outlook
Metropolis is targeting EBITDA margins in the range of 27–28 percent over the coming years. Analysts expect a 200 basis point margin expansion between fiscal years 2026 and 2028, supported by the company’s focus on core margin improvement. While total expenses rose to Rs 363.19 crore in the recent quarter, the company’s ability to manage costs while expanding its footprint remains a key factor for its bullish rating.
Industry Implications and Risks
The diagnostic industry remains highly competitive, and analysts have flagged potential risks, including a sudden uptick in competitive intensity or adverse regulatory rulings. Despite these concerns, the shift toward organized, reliable laboratory services continues to provide a favorable backdrop for incumbents. Investors are now watching for the execution of the 100-hub expansion plan and whether the company can maintain its margin guidance amid rising operational costs. The board’s approval of a second dividend of Re 1 per share further signals management’s confidence in the firm’s cash flow stability and long-term value creation.
